Samuel K. Ackerman

Chief Executive Officer at

Cyclis Pharmaceuticals, Inc.

Health Technology

Finance

Profile

Samuel K.
Ackerman is the founder of Pentose Pharmaceuticals, Inc. He currently holds the position of President & Chief Executive Officer at Cyclis Pharmaceuticals, Inc. and Chairman at Vitex Systems, Inc. Previously, he served as Chairman & Chief Executive Officer at V.I.
Technologies, Inc. from 1999 to 2005, Chairman, President & Chief Executive Officer at Panacos Pharmaceuticals, Inc. from 2005 to 2006, and as a Principal at OraVax, Inc. in 1995.
He also worked as a Partner at Ampersand Management LLC.

Samuel K. Ackerman active positions

Companies	Position	Start
Cyclis Pharmaceuticals, Inc. Cyclis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops small molecule drugs for the treatment of cancer	Chief Executive Officer	-
Vitex Systems, Inc.	Chairman	-

All active positions of Samuel K. Ackerman

Former positions of Samuel K. Ackerman

Companies	Position	End
PANACOS PHARMACEUTICALS, INC.	Chief Executive Officer	15/06/2006
V.I. Technologies, Inc. V.I. Technologies, Inc. BiotechnologyHealth Technology Develops blood products and systems using its proprietary viral inactivation technologies	Chairman	01/08/2005
OraVax, Inc. OraVax, Inc. BiotechnologyHealth Technology Develops oral vaccines and non injected antibody products	Corporate Officer/Principal	31/12/1995
Pentose Pharmaceuticals, Inc. Pentose Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel antiviral products	Founder	-
Ampersand Management LLC Ampersand Management LLC Investment ManagersFinance Ampersand Management invests in companies located in North America, Europe and APAC with an EBITDA of USD 2 - 40 million and revenues of USD 10 - 200 million. The firm targets companies operating in the fields of contract manufacturing, pharma services, specialty products, laboratory products and laboratory services. It participates in MBOs, corporate divestitures, recapitalization and growth stage capital requirements with an investment size of USD 10 - 200 million. The firm acquires majority and minority interests.	Private Equity Investor	-

See the detail of Samuel K. Ackerman's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Samuel K. Ackerman's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	7
OraVax, Inc. OraVax, Inc. BiotechnologyHealth Technology Develops oral vaccines and non injected antibody products	Health Technology
V.I. Technologies, Inc. V.I. Technologies, Inc. BiotechnologyHealth Technology Develops blood products and systems using its proprietary viral inactivation technologies	Health Technology
Vitex Systems, Inc.
Ampersand Management LLC Ampersand Management LLC Investment ManagersFinance Ampersand Management invests in companies located in North America, Europe and APAC with an EBITDA of USD 2 - 40 million and revenues of USD 10 - 200 million. The firm targets companies operating in the fields of contract manufacturing, pharma services, specialty products, laboratory products and laboratory services. It participates in MBOs, corporate divestitures, recapitalization and growth stage capital requirements with an investment size of USD 10 - 200 million. The firm acquires majority and minority interests.	Finance
Pentose Pharmaceuticals, Inc. Pentose Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel antiviral products	Health Technology
Cyclis Pharmaceuticals, Inc. Cyclis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops small molecule drugs for the treatment of cancer	Health Technology
Panacos Pharmaceuticals, Inc. Panacos Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small molecule drugs	Health Technology